What is IPSC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.27B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IPSC?

P/E (TTM) is n/a and 52-week range is $0.43 to $3.04 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IPSC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IPSC?

The company profile lists revenue (TTM) near $115M, net income (TTM) near $-2.17B, EPS (TTM) near $-0.90 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Century Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Philadelphia, Pennsylvania, US, 180.3M shares outstanding, ISIN US15673T1007 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Century Therapeutics Inc

$IPSC

Health Care · Biotechnology

IR Run Scenarios

$1.47

+0.68%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 78 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Employees

Website

www.centurytx.com/

IPO

2021-06-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)